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Abstract: Adiponectin is gaining renewed interest since, in addition to its possible protective role
against insulin resistance and arteriosclerosis, recent studies suggest other additional favorable
effects. However, the influence of gene-diet interactions on plasma adiponectin levels is still little
understood. We analyzed the association between plasma adiponectin levels and various metabolic
traits in a high-cardiovascular risk Mediterranean population, as well as the genetic effect of four
candidate single-nucleotide polymorphisms (SNPs) in the adiponectin gene (ADIPOQ) and their
interactions with the Mediterranean dietary pattern. Additionally, we explored, at the genome-wide
level, the SNPs most associated with plasma adiponectin levels, as well as gene–diet interactions with
the Mediterranean diet. In the 954 participants studied (aged 55–80 years), plasma adiponectin levels
were strongly associated with plasma HDL-C concentrations (p = 6.6 × 10−36) and inversely related to
triglycerides (p = 4.7 × 10−18), fasting glucose (p = 3.5 × 10−16) and type 2 diabetes (p = 1.4 × 10−7).
Of the four pre-selected ADIPOQ candidate SNPs, the one most associated with plasma adiponectin
was the −11391G > A (rs17300539) promoter SNP (p = 7.2 × 10−5, in the multivariable adjusted
model). No significant interactions with the Mediterranean diet pattern were observed for these
SNPs. Additionally, in the exploratory genome-wide association study (GWAS), we found new SNPs
associated with adiponectin concentrations at the suggestive genome-wide level (p < 1 × 10−5) for the
whole population, including the lead SNP rs9738548 (intergenic) and rs11647294 in the VAT1L (Vesicle
Amine Transport 1 Like) gene. We also found other promising SNPs on exploring different strata such
as men, women, diabetics and non-diabetics (p = 3.5 × 10−8 for rs2850066). Similarly, we explored
gene–Mediterranean diet interactions at the GWAS level and identified several SNPs with gene–diet
interactions at p < 1 × 10−5. A remarkable gene–diet interaction was revealed for the rs2917570 SNP
in the OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like) gene, previously reported
to be associated with adiponectin levels in some populations. Our results suggest that, in this
high-cardiovascular risk Mediterranean population, and even though adiponectin is favorably
associated with metabolic traits and lower type 2 diabetes, the gene variants more associated with
adiponectin may be population-specific, and some suggestive gene–Mediterranean diet interactions
were detected.
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1. Introduction
Since the discovery of adiponectin in 1995 [1], this hormone, mainly secreted by
the adipose tissue and initially called adipocyte complement-related protein of 30 kDa
(Acrp30), has drawn a great deal of attention due to its possible protective effect against
type 2 diabetes, its anti-inflammatory effects and its anti-atherogenic properties [2–5].
It has also aroused controversy, given that although various studies reported that high
plasma adiponectin levels were associated with lower cardiovascular disease risk [6–9],
others were unable to confirm its protective effect against cardiovascular diseases or total
mortality [10–12].
Given the interest that adiponectin has aroused, there is a large number of stud-
ies that have analyzed its associations with various adiposity parameters, insulin resis-
tance, plasma lipid levels, inflammatory markers, type 2 diabetes risk and atherosclerosis
biomarkers [13–18]. Although the results of several studies may differ, there is strong con-
sistency in observing that adiponectin appears to increase insulin sensitivity by improving
glucose and lipid metabolisms. Despite the fact that several studies have indicated that
different foods or dietary patterns may increase plasma adiponectin levels [19–26], the
truth is that there is scarce evidence on the role of the various dietary components on
adiponectinemia. Moreover, adiponectin levels may have an important genetic compo-
nent [27–31].
Although various candidate genes have been studied [29,32,33] and several genome-
wide association studies (GWASs) have been undertaken [34–45], the polymorphisms in
the main genes identified so far only account for 5% of the plasma adiponectin variation,
leaving many genes yet to be identified. The leading candidate gene for adiponectin levels
is the ADIPOQ (adiponectin) gene on chromosome 3 [32]. This gene has been identified
as the main signal in several GWASs carried out in European populations or in white
Caucasians [35,41–45]. However, in Asian populations, the strongest signal statistically
associated with adiponectin levels is located in the CDH13 (T-cadherin) gene, chromosome
16 [34,36–41]. Besides these signals, and depending on the population in which the study
was undertaken, other top-ranked single-nucleotide polymorphisms (SNPs) in genes such
as TRIB1 (Tribbles Pseudokinase), DNAH10 (Dynein heavy chain 10, axonemal) and PEPD
(Peptidase D) were identified that reached a high level of statistical significance, but which
differed greatly depending on the populations, therefore being highly inconsistent [35–45].
Even in a large GWAS meta-analysis, including more than 45,000 participants [41,44],
it was not possible to strongly identify, at the GWAS level, a greater number of novel
genes and gene variants associated with plasma adiponectin levels. That would suggest
that, besides the possible ethnic differences depending on the geographical origin of the
population, other environmental modulations such as diet and other lifestyle variables, as
well as sex, age, obesity and type 2 diabetes, among others, may have had an influence on
the results of the GWAS. Furthermore, most studies on candidate genes [46–50], as well as
all the GWASs [35–45], focused on studying the genetic contribution without taking modu-
lation by diet into account. Only very few studies focusing on candidate genes analyzed
gene-diet interactions for adiponectin concentrations [51–54]. It is, therefore, essential
to increase knowledge on the main gene–diet interactions determining both the plasma
adiponectin levels at the candidate gene and genome-wide levels. Moreover, bearing in
mind that the Mediterranean population has scarcely been included in adiponectin GWASs
and that the Mediterranean diet can modulate genetic influence through different gene-diet
interactions [55], our aims were as follows:
(1) To study the association between four pre-selected candidate gene variants: −11391
G/A (rs17300539); +45T > G (rs2241766); +276G > T (rs1501299); and rs17366568 (G > A),
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in the ADIPOQ gene on adiponectin levels and related traits (plasma lipids, adiposity
and type 2 diabetes), as the main effect, and to analyze the gene-diet interactions with the
Mediterranean dietary pattern in a high-cardiovascular risk Mediterranean population.
(2) To undertake an exploratory GWAS to scan the gene variants most associated with
plasma adiponectin levels in this population. Finally, (3) to explore, at the genome-wide
level, the potential gene-Mediterranean diet interactions determining plasma adiponectin
concentrations in this population.
2. Materials and Methods
2.1. Study Design and Participants
We carried out a cross-sectional study on 954 elderly high-cardiovascular risk Mediter-
ranean subjects. These white subjects of European ancestry were recruited in the PRED-
IMED (Prevención con Dieta Mediterránea)-Valencia study [56]. The Valencia field center is
located on the Mediterranean coast of the Iberian Peninsula (Spain). The subjects included
in this study were those who had plasma adiponectin determination available at the base-
line visit. These participants were recruited in primary health care centers, the inclusion
criteria being as follows: elderly (between 55 and 80 years old for men and between 60 and
80 years old for women) and having a high cardiovascular risk, even though they were
free of cardiovascular disease at baseline. Eligible subjects fulfilled at least one of the two
criteria: type 2 diabetes; three or more of the following cardiovascular risk factors: current
smoking; hypertension; dyslipidemia; body mass index (BMI) ≥ 25 kg/m2; and/or family
history of premature cardiovascular disease [57,58]. These participants were recruited
in the various primary health care centers of the Valencia region. Participants provided
written informed consent and study protocols and procedures were approved according
to the ethical standards of the Helsinki Declaration and by the Human Research Ethics
Committee of Valencia University, Valencia (ethical approval code H1422226460525).
2.2. Baseline Anthropometric, Clinical, Biochemical and Lifestyle Variables
Anthropometric variables and blood pressure were determined at baseline by trained
staff. Weight and height were measured with light clothing and no shoes with calibrated
scales and a wall-mounted stadiometer, respectively, as previously reported. BMI was
calculated as the weight (in kg) divided by the height (in m2). Obesity was defined as a
BMI ≥ 30 kg/m2. Waist circumference was measured midway between the lowest rib and
the iliac crest, after normal exhalation, using an anthropometric tape [56,58]. Further, in
the baseline examination, we assessed demographic factors, cardiovascular risk factors,
medications and lifestyle variables by validated questionnaires [58,59]. Type 2 diabetes was
defined according to the criteria of the American Diabetes Association-2018, as previously
reported [57,58]. Blood pressure was measured by trained personnel using a validated
semi-automatic oscillometer (Omron HEM-70CP; Hoofddorp, The Netherlands) with
the subject seated. Physical activity was estimated by the validated Minnesota Leisure-
Time Physical Activity questionnaire as previously reported [56–58]. Smoking status was
assessed by the World Health Organization questionnaire including five categories as
previously reported [56–59]. Here, non-smokers and ex-smokers were combined and
compared with current smokers. Thus, a dichotomic variable was used for smoking status.
As dietary variables for this study, we focused on the Mediterranean diet pattern.
To measure the Mediterranean diet pattern, we used a validated 14-item scale [60], also
administered at baseline. Detailed items of that scale with their response options are
presented in Supplemental Table S1. Each question was scored 0 or 1. The final score ranged
from 0 to 14. The higher the score, the greater the adherence to the Mediterranean diet. The
degree of adherence was later dichotomized into high (≥9) and low (<9) depending on the
population mean (9 points).
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2.3. Biochemical Determinations and Plasma Adiponectin Measures
Blood samples were collected after a 12-h overnight fast. Fasting glucose, total choles-
terol, triglycerides and HDL cholesterol (HDL-C) were measured using standard enzymatic
automated methods as previously described [56,58]. In patients whose triglyceride levels
were <400 mg/dL, LDL-C concentrations were estimated using the Friedewald formula. In
addition, fasting blood samples were obtained for each participant and plasma was stored
at −80 ◦C until further biochemical analyses. Fasting plasma adiponectin concentrations
were measured and determined using an enzyme-linked immunosorbent assay (ELISA)
kit (Cat. # EZHADP-61K), supplied by Linco Research, St. Charles, MO, USA, according
to the manufacturer’s instructions. The absorbance was read at 450 nm using the Multi-
skan EX spectrophotometer (Thermo Electron Corporation, Milford, NH, USA) and the
Ascent Software program (Thermo Labsystems, Vantaa, Finland). All determinations were
made in duplicate. Adiponectin concentrations were expressed in µg/mL. The intra-assay
coefficient of variation was 1.2% and that of the inter-assay was 2.1%.
2.4. DNA Isolation and Genotyping
Genomic DNA was isolated from blood. The quantity of double-stranded DNA was
measured using PicoGreen (Invitrogen Corporation, Carlsbad, CA, USA). Firstly, we se-
lected the relevant polymorphisms in the adiponectin gene (ADIPOQ) and undertook their
specific genotyping. The four polymorphisms selected were initially the most commonly
studied: a promoter variant, −11391 G/A (rs17300539) [49]; the T to G substitution in exon
2 (+45T > G, rs2241766); the G to T substitution in intron 2 (+276G > T, rs1501299) [47–49];
and rs17366568 (G > A) in intron 3 [35]. The SNPs (rs17300539 and rs2241766) in the
ADIPOQ gene were determined by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) [61] using MspI and SmaI, respectively. TaqMan real-time
PCR using pre-designed assays for allelic discrimination, containing specific probes for
each allele (ThermoFisher Scientific, Waltham, MA, USA), was used for the rs1501299 and
the rs17366568 genotyping (C_7497299_10 and C_33187752_10, respectively) on a 7900HT
Sequence Detection system (Applied Biosystems, Foster City, CA, USA) [20]. Quality
control measures of SNP genotyping were carried out including replicate quality control
samples (10%) and no deviation from the Hardy-Weinberg equilibrium testing.
Besides the genotyping of these pre-selected polymorphisms in the ADIPOQ gene,
a high-density genotyping at the genome-wide level using the Infinium OmniExpress-
24 BeadChip genotyping array (v1.0 and v1.1) (Illumina Inc., San Diego, CA, USA) was
then carried out. This array captures approximately 720,000 markers (the number varies
depending on the version used: 730,000 for v.1.0 and 716,000 for v.1.1), and 699,221 markers
that are common to both versions of the array (v1.0 and v.1.1) were used. Genome-wide
genotyping was performed at the University of Valencia according to the manufacturer’s
protocol with appropriate quality standards as previously reported [56]. Allele detection
and genotype calling were performed in the GenomeStudio genotyping module (Illumina,
Inc.). Data cleaning was performed using standard analysis pipelines implemented in the
Phyton programming language combined with PLINK [62,63]. We filtered out the SNPs
not mapped on autosomal chromosomes. In addition, SNPs with a minor allele frequency
(MAF) <0.01 or those that deviated from the expected Hardy-Weinberg equilibrium (p <
1.0 × 10−4) and SNPs with a call rate < 90% were removed. Then, 625,127 variants passed
quality controls with a total genotyping rate of 0.9964. Finally, besides the GWAS analysis
of all the chip’s SNPs that surpassed the quality controls, we undertook a search for SNPs
of the ADIPOQ gene that were included in the OmniExpress-24 BeadChip genotyping
array (v1.0 and v1.1) so as to specifically extract these results and analyze them as SNPs in
candidate genes. Likewise, as the CDH13 gene is another of the candidates that has been
associated with adiponectin levels in many GWASs, we also pre-selected this gene as a
candidate and extracted the SNPs that, for that gene, are found in the OmniExpress-24
BeadChip genotyping array. The corresponding genotype data were extracted by a Python
script, created by the authors using the batch query resource SNP Report as previously
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reported [56]. Finally, the Python script produced the corresponding PLINK *.ped and
*.map files of genotypes for statistical testing.
For SNP annotation (assigning the corresponding Gene Symbol to each rsID), we cre-
ated a Phyton (version 3.7.4, 8 July 2019) script. This script uses an annotation database, de-
signed and built with the database platform SQLite (version 3.33.0, 14 August 2020) (https:
//www.sqlite.org, accessed on 24 January 2021), containing data imported from the In-
finium OmniExpress-24 BeadChip v1.2 genotyping array manifest (GRCh37) (https://emea.
support.illumina.com/downloads/infinium-omniexpress-24-v1-2-product-files.html, ac-
cessed on 24 January 2021), and verified and completed with the NCBI SNP database (
https://www.ncbi.nlm.nih.gov/snp/, accessed on 24 January 2021, GRCh37 and GRCh38)
data. In the case of intergenic SNPs, no Gene Symbol is assigned.
2.5. Statistical Analysis
2.5.1. General Associations and Candidate Gene Analysis
Plasma adiponectin and triglyceride levels were log-transformed (Ln) for the statistical
analyses. First of all, we carried out descriptive statistical tests to summarize the character-
istics of the sample studied. Chi-square tests were used to compare proportions. Student
t-tests and ANOVA tests were applied to compare crude means of continuous variables.
To estimate the association between adiponectin levels and plasma lipids, fasting glucose
and adiposity-related variables, Spearman rank correlation coefficients were calculated.
Analyses were carried out in the whole population and stratified by sex and diabetes status.
To study the association between the four pre-selected SNPs (−11391 G/A, rs17300539;
+45T > G, rs2241766; +276G > T, rs1501299; and rs17366568 G > A) in the ADIPOQ gene and
plasma adiponectin levels, general linear models, unadjusted and adjusted for potential
confounders, were used. Models were sequentially fitted as follows: model 1, unadjusted;
model 2, adjusted for age and sex; model 3, additionally adjusted for type 2 diabetes;
and model 4, additionally adjusted for BMI. Further adjustment for smoking, physical
activity and adherence to the Mediterranean diet was carried out when indicated. Ad-
justed means for continuous variables were estimated from the multivariable adjusted
general linear models. The genetic effect for SNPs was considered as additive (alleles 0,
1, and 2 for the minor allele). To test gene–diet interactions between the four pre-selected
ADIPOQ polymorphisms and the Mediterranean diet pattern, we used the 14-item score
as a categorical variable. To do so, we considered two categories based on the population
mean: low adherence to the Mediterranean diet (8 points or lower) or high adherence to
the Mediterranean diet (score of 9 points or higher). We also tested the interaction with
the adherence variable as continuous with 14 points in order to compare results, when
indicated. To analyze the gene-diet interactions in determining adiponectin concentrations,
general linear hierarchical models were used in which the main effects and the interaction
term were included. In each analysis, the confounding variables for adjustment were
indicated in the tests. Besides testing the associations of the pre-selected polymorphisms in
the ADIPOQ gene with adiponectin levels, associations with plasma lipid levels, fasting
glucose and anthropometric variables were also tested for the most relevant pre-selected
SNP. Likewise, gene-diet interactions with the Mediterranean diet for these variables were
computed. In addition, the associations of the most significant ADIPOQ polymorphism, as
well as the gene-diet interactions, considering prevalent type 2 diabetes as the outcome
variable, were tested. Thus, uni- and multi-variant logistic regression models were used
(including interaction terms or not, depending on the case). Odds ratios (OR) and 95%
confidence intervals (CI) for the corresponding variables were estimated. Analyses were
undertaken for the whole population and stratified by sex when indicated. These statistical
analyses were performed with IBM SPSS Statistics (version 26.0), New York, NY, USA. All
tests were two-tailed and p-values < 0.05 were considered statistically significant for these
associations.
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2.5.2. GWASs Analyses
For the GWAS on adiponectin levels (Ln-transformed), association analyses were
carried out using PLINK v1.9 [62,63]. Additive genetic models were fitted. General
linear regression models were used, and regression coefficients and standard error (SE)
were estimated. Model 1 (unadjusted), model 2 (adjusted for sex and age), model 3
(additionally adjusted for diabetes) and model 4 (adjusted for sex, age, diabetes and BMI)
were computed. Beta regression coefficients for the minor allele were obtained. These
analyses were performed in the whole population and stratified by sex and type 2 diabetes
when indicated. Moreover, gene-Mediterranean diet interactions at the genome-wide level
(including all the array SNPs that passed the quality control, as previously mentioned)
in determining plasma adiponectin levels were analyzed. Additive genetic models were
considered for the SNPs, and the Mediterranean diet was analyzed as categorical (low and
high adherence). Hierarchical general linear regression models were fitted and the p-values
for the SNP-diet interactions terms were computed.
We applied the conventional threshold of p < 5 × 10−8 for genome-wide statistical
significance, as well as the standard p-value for suggestive genome-wide significance
(p < 1 × 10−5).
We used Haploview (version 4.2) [64] and Functional Mapping and Annotation of
Genome-Wide Association Studies (FUMA) [65] to create Manhattan plots and to calculate
the linkage disequilibrium (LD) between the SNPs of interest. Quantile-quantile plots
comparing the expected and observed p-values were performed in the R-statistical environ-
ment and with FUMA [65,66]. We used LocusZoom-Single Plot (http://locuszoom.org/;
accessed on 24 January 2021) and LocusZoom.js (https://my.locuszoom.org/, accessed on
24 January 2021) to generate locus-specific graphical displays of the position of the selected
SNPs in the GWAS to nearby genes and local recombination hotspots [67], as well as to
indicate the LD. SNiPA, a tool for annotating and browsing genetic variants [68], was also
used to display the LD between the selected SNPs and the nearby SNPs in regional plots
using data from the European population based on the 1000 Genomes Project, incorporated
in that tool.
Finally, we carried out additional association analyses for some top-ranked interesting
SNPs as potentially novel signals for plasma adiponectin, including stratification by sex or
by Mediterranean diet adherence strata, and additional adjustment for co-variates.
3. Results
3.1. Participant Characteristics
The demographic, anthropometric, clinical, biochemical and lifestyle characteristics of
the study participants at baseline are presented in Table 1.
We included 954 subjects (348 men and 606 women) that, in addition to the general
variables of the study, had plasma adiponectin measured at baseline available. They
consisted of older men and women (mean age 67 ± 0.2 years). Mean adiponectin levels
were 7.8 ± 0.2 for men and 11.9 ± 0.2 µg/mL for women. We used these values as sex-
specific cut-off points to create a sex-specific dichotomous variable to define low and high
adiponectin levels, taking into account the strong differences per sex. Prevalence of type
2 diabetes was high (47.2%) in the whole population. Obesity prevalence was also high
(50.1% in the whole population).
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(n = 606) p
Age (years) 67.0 ± 0.2 66.2 ± 0.4 67.4 ± 0.2 0.007
Weight (kg) 76.3 ± 0.4 81.5 ± 0.6 73.4 ± 0.4 <0.001
BMI (kg/m2) 30.3 ± 0.1 29.6 ± 0.2 30.7 ± 0.2 <0.001
Waist circumference (cm) 102.5 ± 0.4 104.2 ± 0.6 101.5 ± 0.5 0.001
SBP (mm Hg) 146.8 ± 0.7 148.3 ± 1.1 145.9 ± 0.9 0.086
DBP (mm Hg) 81.9 ± 0.3 82.6 ± 0.6 81.4 ± 0.4 0.099
Total cholesterol (mg/dL) 207.7 ± 1.3 199.7 ± 2.0 212.3 ± 1.6 <0.001
LDL-C (mg/dL) 129.1 ± 1.2 124.5 ± 1.9 131.6 ± 1.5 0.004
HDL-C (mg/dL) 52.5 ± 0.4 47.9 ± 0.6 55.1 ± 0.6 <0.001
Triglycerides 1 (mg/dL) 131.5 ± 2.3 136.6 ± 3.7 128.6 ± 2.8 0.051
Fasting glucose (mg/dL) 120.4 ± 1.3 128.3 ± 2.2 115.8 ± 1.5 <0.001
Plasma adiponectin 2 (µg/mL) 10.4 ± 0.2 7.8 ± 0.2 11.9 ± 0.2 <0.001
Physical activity (MET-min/day) 166 ± 6 216 ± 12 137 ± 5 <0.001
Adherence to MedDiet (P14) 3 8.0 ± 2.8 7.9 ± 2.8 8.1 ± 2.7 0.130
High adherence MedDiet 4 476 (50.0) 177 (51.0) 299 (49.4) 0.637
Current smokers: n, % 116 (12.2) 88 (25.3) 28 (4.6) <0.001
Type 2 diabetes: n, % 450 (47.2) 197 (56.6) 253 (41.7) <0.001
Obesity: n, % 478 (50.1) 151 (43.4) 327 (54.0) 0.002
Values are mean ± standard error (SE) for continuous variables and number (%) for categorical variables. BMI:
body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL-C: high-density lipoprotein
cholesterol; HDL-C: low-density lipoprotein cholesterol; MET: metabolic equivalent.; P: p-value for the compar-
isons between men and women. Student’s t tests were used to compare means and chi-squared tests were used to
compare categories. 1: Triglycerides were ln-transformed for statistical testing. 2: Adiponectin concentrations
were ln-transformed for statistical testing. 3: Using the 14-item questionnaire for adherence to the Mediterranean
diet (MedDiet). 4: High adherence to the MedDiet: score ≥ 9.
3.2. Associations between Plasma Adiponectin and Fasting Glucose, Plasma Lipids, Adiposity
Variables and Type 2 Diabetes
Table 2 shows associations between plasma adiponectin and fasting glucose, lipids and
adiposity in the whole population and per sex. In the whole population, adiponectin was
positively correlated with HDL-C (r = 0.39; p = 5.6 × 10−36) and negatively correlated with
triglycerides (r = −0.28; p = 4.7 × 10−18) and fasting glucose (r = −0.26; p = 3.5 × 10−16).
A significant inverse correlation at p = 0.006 was also found between adiponectin and
waist circumference, although the correlation coefficient was relatively weak (r = −0.009).
Similar results were found for men and women, although higher associations were detected
in women.
Table 3 shows the association between adiponectin and type 2 diabetes at baseline.
High plasma adiponectin was associated with lower type 2 diabetes risk in the whole
population (OR = 0.61; 95%CI: 0.46–0.80; p = 4.4 × 10−4) for the dichotomous variable
for adiponectin (high versus low concentrations), in a model adjusted for sex, age, BMI,
smoking, physical activity and adherence to the Mediterranean diet. Likewise, when the
continuous variable for adiponectin concentrations was used, we observed a strong inverse
association, indicating the importance of the dose–effect. In the multivariate adjusted
model, the OR was 0.47; 95%CI (0.35–0.63), p = 3.0 × 10−7, per unit increase in adiponectin.
On analyzing the results per sex, higher protection was observed in women.
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Fasting glucose (mg/dL) r
2 −0.261 −0.109 −0.271
p 3 3.48 × 10−16 0.043 1.42 × 10−11
Tryglicerides (mg/dL) r
2 −0.276 −0.169 −0.340
p 3 4.72 × 10−18 1.59 × 10−3 8.17 × 10−18
HDL-C (mg/dL) r
2 0.391 0.292 0.342
p 3 5.59 × 10−36 3.03 × 10−8 5.00 × 10−18
LDL-C (mg/dL) r
2 0.109 0.084 0.077
p 3 8.52 × 10−4 0.122 0.059
BMI (Kg/m2)
r 2 0.029 0.068 −0.075
p 3 0.367 0.209 0.064
Waist circumference (cm) r
2 −0.090 0.032 −0.093
p 3 0.006 0.559 0.024
1: Metabolic traits measured in fasting status for the whole population (n = 954 participants, including n = 348 men
and n = 606 women). 2: r (normal) is the Spearman correlation coefficient. 3: p-value (italics) for the Spearman
correlation coefficient.
Table 3. Association between adiponectin levels (as dichotomous and continuous variable) and type 2 diabetes in the whole





5 OR 3 and 95%
CI p




Model 1 2 0.65 (0.49–0.84) 0.001 0.77 (0.50–1.19) 0.239 0.59 (0.42–0.82) 0.002
Model 2 3 0.61 (0.46–0.79) 2.80 × 10−4 0.68 (0.43–1.06) 0.090 0.57 (0.41–0.81) 0.001
Model 3 4 0.61 (0.46–0.80) 4.40 × 10−4 0.67 (0.42–1.07) 0.093 0.59 (0.42–0.85) 0.004
Continuous variable 6
Model 1 2 0.46 (0.35–0.59) 3.00 × 10−9 0.69 (0.48–1.09) 0.097 0.42 (0.29–0.59) 1.01 × 10−6
Model 2 3 0.47 (0.35–0.62) 1.41 × 10−7 0.64 (0.39–1.03) 0.065 0.40 (0.28–0.57) 6.40 × 10−7
Model 3 4 0.47 (0.35–0.63) 3.03 × 10−7 0.64 (0.39–1.03) 0.066 0.42 (0.29–0.61) 3.10 × 10−5
OR: odds ratio; CI: confidence interval. 1: A categorical variable for low and high adiponectin concentration was created taking into account
sex-specific levels (high ≥7.8 (µg/mL) for men, and ≥11.9 (µg/mL) for women). OR indicates the risk for high level versus low level.
2: Unadjusted regression model. 3: Model adjusted for sex, age and BMI. 4: Model adjusted for sex, age, BMI, physical activity, current
smokers and adherence to the Mediterranean diet. 5: p-value obtained in the corresponding logistic regression model. 6: Adiponectin
(µg/mL) was used as a continuous variable (ln-transformed) and the OR indicates the risk per unit.
3.3. Association between the Pre-Selected ADIPOQ SNPs and Plasma Adiponectin
Concentrations. Interactions with Adherence to the Mediterranean Diet
First, we analyzed the association between adiponectin and adherence to the Mediter-
ranean diet score. We did not detect any statistically significant differences in plasma
adiponectin depending on the low or high level of adherence to the Mediterranean diet
(p = 0.531) after multivariate adjustment for sex, age, type 2 diabetes, BMI, smoking and
physical activity. To identify specific foods relevant for adiponectin levels on this pattern,
we also examined the association with specific food items included in the Mediterranean
diet score. Sex-specific adiponectin levels were used, bearing in mind that adiponectin
is significantly higher in women (p = 1.37 × 10−30). Thus, according to the cut-off val-
ues defined by the corresponding adiponectin means for men and women in Table 1, a
dichotomous variable for sex-specific low and high adiponectin levels was created. In this
categorical variable, low adiponectin levels were defined as having plasma adiponectin lev-
els lower than 7.8 for men and less than 11.9 µg/mL for women. Likewise, high adiponectin
levels were levels ≥ 7.8 or 11.9 µg/mL for men and women, respectively. Supplementary
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Table S2 shows the association between all the foods included in the Mediterranean diet
adherence pattern score and the sex-specific adiponectin levels (low and high). No statisti-
cally significant associations for any food items were observed (p > 0.05 for all). Therefore,
we used the total score for adherence to the Mediterranean diet as the main variable to test
gene-diet interactions in further analyses.
Later, we examined the association between the four pre-selected candidate SNPs in
the ADIPOQ gene: −11391 G/A (rs17300539); the T to G substitution in exon 2 (+45T > G,
rs2241766); the G to T substitution in intron 2 (+276G > T, rs1501299); and rs17366568
(G > A) in intron 3, and adiponectin concentrations. Table 4 shows adiponectin means
per genotype for each SNP. We only observed strong and additive associations for the
−11391 G/A (rs17300539) polymorphism. The minor allele was associated with statistically
significant higher adiponectin concentrations (p = 7.2 × 10−5) in the multivariable adjusted
model.
Table 4. Association between the 4 pre-selected ADIPOQ candidate single-nucleotide polymorphisms (SNPs) and









Mean ± SE p
1 p 2 p-Int
3
MedDiet
−11391 G > A (rs17300539) 4 10.09 ± 0.20 11.45 ± 0.47 13.45 ± 1.00 4.80 × 10−4 7.20 × 10−5 0.559
+45T > G (rs2241766) in exon 2 5 10.41 ± 0.22 10.37 ± 0.36 11.40 ± 0.89 0.436 0.808 0.072
+276G > T (rs1501299) in intron 2 6 10.33 ± 0.25 10.26 ± 0.30 12.02 ± 0.69 0.091 0.047 0.795
rs17366568 (G > A) 7 10.49 ± 0.20 10.39 ± 0.46 8.57 ± 1.39 0.271 0.257 0.525
Multivariable adjusted models and gene-diet interactions with adherence to the Mediterranean diet. 11, 12 and 22 indicate the three
genotypes for each SNP: 1 major allele, 2 minor alleles. Mean adiponectin concentrations are expressed in µg/mL. 1: p-value obtained in
the unadjusted general linear additive model. 2: p-value obtained in the general linear additive model adjusted for sex, age, diabetes, BMI,
physical activity, smoking and adherence to the Mediterranean diet. 3: p-value for the interaction term between the corresponding SNP and
adherence to the Mediterranean diet in the multivariable model 2. 4: Genotype prevalence was 78.4% GG; 19.6% GA; and 2.0% AA (n = 951).
5: Genotype prevalence was 67.2% TT; 28.9% TG; and 3.9% GG (n = 954). 6: Genotype prevalence was 51.9% GG; 39.2% GT; and 8.9% TT
(n = 941). 7: Genotype prevalence was 79.4% GG; 19.3% GA; and 1.3% AA (n = 948). Ln-transformed adiponectin (µg/mL) for p-values.
For +276G > T (rs1501299), we obtained borderline significant associations. Inter-
estingly, no statistically significant associations with adiponectin concentrations were
observed for the rs17366568 (G > A) SNP (p = 0.257). This SNP was the most significantly
associated with adiponectin levels (identified as the lead SNP) in the meta-analysis carried
out in several European populations and published by Heid et al. (35). However, in
this meta-analysis, the rs17366568 (G > A) SNP did not reach the statistical significance
(p = 0.481) for the only Mediterranean population analyzed (from Italy, the InChianti
study), suggesting potential population-specific differences in the ADIPOQ architecture
and associations.
Regarding gene-diet interactions, we did not detect any statistically significant inter-
actions between each one of the four pre-selected ADIPOQ candidate SNPs and adherence
to the Mediterranean diet in determining plasma adiponectin concentrations in the whole
population (p > 0.05 for all).
Supplemental Table S3 presents the associations and gene-diet interactions with the
Mediterranean diet between the −11391 G/A (rs17300539) polymorphism and metabolic
traits. Despite the strong association between this SNP and plasma adiponectin concentra-
tions, no significant associations were obtained for this polymorphism and fasting glucose,
BMI, waist circumference, HDL-C or type 2 diabetes.
3.4. GWAS for Plasma Adiponectin Concentrations in the Whole Population
We first carried out a GWAS for plasma adiponectin concentrations (ln-transformed)
according to model 1 (unadjusted additive genetic model). We obtained several associations
at the suggestive genome-wide significance level (p < 1.0 × 10−5). The lead SNP in this
model was rs6705747, intergenic on chromosome 2 with p = 1.32 × 10−7 and MAF: 0.294.
Nutrients 2021, 13, 541 10 of 24
The second top-ranked SNP (p = 1.65 × 10−6) was rs11647294 (intronic) in the VAT1L
(Vesicle Amine Transport 1 Like) gene on chromosome 16 with a high MAF (0.401) in
comparison with the other top-ranked SNPs. This is the first time an SNP in the VAT1L
gene is suggested to be related to adiponectin levels.
After adjustment for sex and age, the statistical significance for the VAT1L SNP was
6.9 × 10−6. After additional adjustment for diabetes and BMI, the statistical significance of
the rs11647294-VAT1L SNP was attenuated (p = 1.0 × 10−5), and other SNPs reached more
statistical significance. Supplemental Figure S1 presents the corresponding Manhattan
plot showing the p-value (−log10 p) of each SNP analyzed in the model adjusted for
sex, age, diabetes and BMI. Supplemental Figure S2 shows the corresponding Q-Q plot.
Table 5 shows more detailed information on the top-ranked SNPs in the GWAS on plasma
adiponectin concentrations adjusted for sex, age, type 2 diabetes and BMI, including the
position, the effect (beta regression coefficient), the p-value, the corresponding MAF and
the annotated gene.
Table 5. Top-ranked SNPs in the genome-wide association study (GWAS) for adiponectin concentrations (ln-transformed)
in the whole population.
Chr SNP BP Beta p Alleles MAF Strand Gene
12 rs9738548 128533430 0.141 1.07 × 10−6 T 0.137 + intergenic
13 rs396318 56590135 0.247 3.03 × 10−6 G 0.129 + intergenic
4 rs17613848 23485012 −0.123 3.72 × 10−6 A 0.135 + LOC105374524
16 rs12149200 678430 0.184 4.43 × 10−6 T 0.020 + RAB40C
4 rs998888 160494830 0.215 8.02 × 10−6 T 0.097 - LOC107986324
11 rs11024603 18306399 0.129 8.77 × 10−6 A 0.228 + HPS5
1 rs6698721 185849364 0.446 1.00 × 10−5 A 0.176 + HMCN1
16 rs11647294 77917661 0.098 1.01 × 10−5 T 0.401 + VAT1L
21 rs2850066 37338018 −0.119 1.02 × 10−5 G 0.273 + LOC101928269
16 rs4785550 48864323 0.183 1.05 × 10−5 T 0.227 + intergenic
Model adjusted for sex, age, diabetes and BMI. BMI: body mass index. Chr: chromosome. SNP: single-nucleotide polymorphism. BP:
base position in the chromosome (Homo Sapiens GRCh37.p13 genome build used in Illumina HumanOmniExpress-24 BeadChip). Beta:
indicates the effect for the minor allele on adiponectin (ln-transformed). P: p-value obtained in the multivariable linear regression model
adjusted for sex, age, diabetes and BMI for each SNP using a genetic additive model. MAF: minor allele frequency.
After this adjustment for sex, age, type 2 diabetes and BMI, the lead SNP in the GWAS
for adiponectin was rs9738548 (intergenic) on chromosome 12 (p = 1.1 × 10−6). Figure 1
shows the regional plot for this lead SNP. The MIR3612 gene is close to this intergenic SNP.
RAB40C (Ras-Related Protein Rab-40C) was also top-ranked at p = 4.4 × 10−6, but
its MAF was relatively low. With a higher MAF (0.228), we detected an SNP in HPS5
(Hermansky-Pudlak syndrome). Figure 2 depicts the regional plot for the rs1124603-
HPS5 SNP.
Figure 3 shows the regional plot corresponding to the rs11647294-VATL1 SNP. This
SNP is close to the NUDT7 gene.
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Figure 1. Regional plot for the lead SNP rs9738548, located on chromosome 12 (intergenic), in the GWAS for adiponectin
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Figure 2. Regional plot for the SNP rs11024603, located in the Hermansky–Pudlak syndrome (HPS5) gene, on chromosome
11 in the GWAS, for adiponectin concentrations in the whole population. p-values obtained in the general linear regression
model adjusted for sex, age, diabetes and BMI.
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Figure 3. Regional plot for the SNP rs11647294, located in the vesicle amine transport 1 like (VAT1L) gene, on chromosome
11 in the GWAS, for adiponectin concentrations in the whole population. p-values obtained in the general linear regression
model adjusted for sex, age, diabetes and BMI.
We considered rs11647294-VATL1 to be a promising candidate SNP for further analyses
into plasma adiponectin concentrations and so studied the homogeneity of the association
with adiponectin per sex strata. Figure 4 presents plasma adiponectin concentrations in
men (panel A) and in women (panel B) depending on the rs11647294-VATL1 SNP. This SNP
was significantly associated with adiponectin concentrations, both in men and in women,
in the unadjusted model. The associations remained statistically significant even after
further adjustment for sex, age, diabetes, BMI, smoking, physical activity and adherence to
the Mediterranean diet.
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VATL1 SNP for the adiponectin GWAS. p-values (ln-transformed) were obtained in the general linear regression models:
unadjusted (1) and adjusted for age, diabetes, BMI, smoking, physical activity and adherence to the Mediterranean diet (2).
Error bars: (SE) of means. Genotype prevalence: GG (42.2%), GA (43.0%) and AA (14.8%).
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3.5. ADIPOQ and CDH13 Genes and Plasma Adiponectin Concentrations in the GWAS
As we did not observe a top-ranked signal for SNPs in the ADIPOQ and CDH13
candidate genes, we examined the specific associations of these SNPs in the GWAS. We
extracted all the ADIPOQ SNPs present in the OmniExpress Illumina array and checked
the associations with plasma adiponectin concentrations. Supplemental Figure S3 presents
the LD plot between the 10 ADIPQ SNPs included in the array and the pre-selected SNPs
analyzed. The −11391 G/A (rs17300539) SNP was not included in the array, and its LD
with other ADIPOQ SNPs is low. This SNP was detected at p = 7.2 × 10−5 in our previous
candidate gene analysis with adiponectin concentrations (a little bit below the suggestive
level of the GWAS significance, p = 1.0 × 10−5). Supplemental Table S4 shows the p-values,
beta and MAF corresponding to the 10 ADIPOQ SNPs included in the array. The most
significant ADIPOQ SNP in the model adjusted for sex, age, diabetes and BMI was the
rs1501299 SNP, the only one that was common to both the array and our pre-selected
list. The association with adiponectin was borderline significant, mimicking the results
previously obtained in the candidate gene analysis.
Supplemental Table S5 presents the associations between the top-ranked CDH13 SNPs
of the CDH13 SNPs included in the array and plasma adiponectin concentrations. Only
one SNP reached statistical significance at the nominal p-value (rs4782726, p = 0.016),
indicating that the CDH13 gene is not a relevant locus for adiponectin concentrations in
this Mediterranean population.
3.6. Stratified GWASs for Plasma Adiponectin
3.6.1. Analysis per Sex
Considering the important differences in adiponectin concentrations between men
and women, we conducted exploratory sex-specific GWASs. Supplemental Table S6 shows
the top-ranked SNPs obtained in the sex-specific GWAS in men (A) and in women (B),
after adjustment for age, BMI and type 2 diabetes. In men, we detected an interesting SNP,
rs5876, located in MFSD14A (Hippocampus abundant transcript 1), also known as HIAT, on
chromosome 1 (p = 2.0 × 10−6). Supplemental Figure S4 shows the LD regional plot for this
SNP. For women, the most significant SNP was rs9989048 in the SYT1 (Synaptotagmin-1)
gene. Supplemental Figure S5 shows the LD regional plot for this SNP.
3.6.2. Analysis per Diabetes Status
In the GWASs stratified by diabetes status (Table 6), we detected a statistically signifi-
cant association at the GWAS level of significance in non-diabetic subjects for the rs2850066
SNP (p = 3.5 × 10−8), in the model adjusted for age, sex and BMI. This SNP is located in
the LOC101928269 gene on chromosome 21.
Figure 5 presents the regional plot for the rs2850066 SNP, located near the MIR802
gene and near the SETD4 (SET Domain Containing 4) genes.
Other SNPs in non-diabetic subjects reached the suggestive genome-wide level of
significance (rs2835220, rs1283468, rs12887387, rs2146971 and rs11024603). In diabetic
subjects, the most significant SNP was rs5992838 (intergenic) with p = 7.73 × 10−6. How-
ever, an interesting top-ranked SNP is rs7616406 in the CAND2 (Cullin Associated And
Neddylation Dissociated 2) gene on chromosome 3. Supplemental Figure S6 shows the
regional plot for this SNP.
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Table 6. Top-ranked SNPs of the GWAS for adiponectin concentrations (ln-transformed) in non-diabetic and diabetic
subjects.
A: Non-Diabetic Subjects
Chr SNP BP Beta p Alleles MAF Strand Gene
21 rs2850066 37338018 −0.189 3.51 × 10−8 G 0.273 + LOC101928269
21 rs2835220 37367098 −0.157 3.18 × 10−7 C 0.283 + LOC101928269
6 rs1283468 70038147 0.200 4.52 × 10−7 A 0.180 + ADGRB3
14 rs12887387 90196183 0.232 1.71 × 10−6 T 0.162 + intergenic
14 rs2146971 90173453 0.198 2.11 × 10−6 T 0.161 - intergenic
11 rs11024603 18306399 0.184 2.36 × 10−6 A 0.228 + HPS5
B: Diabetic Subjects
Chr SNP BP Beta p Alleles MAF Strand Gene
22 rs5992838 18264831 −0.147 7.73 × 10−6 G 0.411 + intergenic
10 rs11239763 43262368 −0.161 1.07 × 10−5 C 0.393 + LOC105378269
9 rs1779307 91449366 0.144 1.09 × 10−5 C 0.356 + intergenic
10 rs11239766 43264591 −0.161 1.35 × 10−5 G 0.386 + LOC105378269
2 rs2290130 232263127 0.168 1.35 × 10−5 A 0.233 - B3GNT7
3 rs7616406 12862257 0.152 1.49 × 10−5 G 0.446 + CAND2
Model adjusted for sex, age and BMI. BMI: body mass index. Chr: chromosome. SNP: single-nucleotide polymorphism. BP: base position
in the chromosome (Homo Sapiens GRCh37.p13 genome build used in Illumina HumanOmniExpress-24 BeadChip). Beta: indicates the
effect for the minor allele on adiponectin concentrations (ln-transformed). P: p-value obtained in the multivariable linear regression model
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Figure 5. Regional plot for the SNP rs280066, located in the LOC101928269 gene, on chromosome 21 in the GWAS, for
adiponectin concentrations in non-diabetic subjects. p-values obtained in the general linear regression model adjusted for
sex, age and BMI.
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3.7. Gene–Mediterranean Diet Interactions for Adiponectin Concentrations at the Genome-Wide
Level
Table 7 shows the top-ranked SNPs in the corresponding exploratory GWAS for
the study of gene-Mediterranean diet interactions. Several SNPs reached the suggestive
genome-wide level of significance for the gene-diet interaction term analyzed. The most
significant interaction term with the Mediterranean diet adherence (low versus high) was
for the rs17249128 SNP (p = 2.5 × 10−7), located in LOC101927334 on chromosome 16.
Supplemental Figure S7 shows the LD regional plot for this SNP.
Table 7. Top-ranked SNPs of the GWAS for gene-diet interactions between the genome-wide SNPs and adherence to the
Mediterranean diet in determining adiponectin concentrations (ln-transformed) in the whole population.
Chr SNP Beta 1 Beta 2 p-Interaction 1 Alleles MAF Strand Gene
16 rs17249128 −0.125 0.123 2.53 × 10−7 G 0.466 + LOC101927334
4 rs828154 0.077 −0.191 9.74 × 10−7 G 0.485 − intergenic
3 rs326251 0.131 −0.097 4.20 × 10−6 C 0.333 − intergenic
11 rs2917570 0.113 −0.118 5.12 × 10−6 T 0.497 + OPCML
4 rs13111850 0.334 −0.130 6.42 × 10−6 C 0.033 + intergenic
2 rs6433691 0.197 −0.162 6.45 × 10−6 A 0.241 + PDE11A
4 rs10019416 −0.093 0.175 7.46 × 10−6 A 0.258 + SLIT2
11 rs3016384 0.118 −0.109 8.05 × 10−6 T 0.491 − OPCML
2 rs3770019 0.206 −0.156 1.09 × 10−5 C 0.141 + PDE11A
8 rs13280216 0.174 −0.100 1.16 × 10−5 A 0.267 + intergenic
2 rs9677333 0.203 −0.156 1.31 × 10−5 C 0.139 + PDE11A
4 rs10023405 −0.119 0.112 1.39 × 10−5 G 0.210 + KIAA1211
10 rs912745 −0.148 0.211 1.44 × 10−5 T 0.092 + LOC102724627
1 rs3219110 0.061 −0.146 1.51 × 10−5 C 0.319 − PARP1
Chr: chromosome. SNP: single-nucleotide polymorphism. BP: base position in the chromosome (Homo Sapiens GRCh37.p13 genome
build used in Illumina HumanOmniExpress-24 BeadChip). Beta: indicates the effect for the minor allele on adiponectin concentrations
(ln-transformed). Beta 1: indicates the regression coefficients for the low adherence to the Mediterranean diet strata (50%). Beta 2: indicates
the regression coefficients for the high adherence to the Mediterranean diet strata, based on the population mean (9 points). 1: p-value
obtained for the interaction term SNP-adherence to the Mediterranean diet in the corresponding hierarchical general linear regression
model including the main effects and interaction terms in the whole population. MAF: minor allele frequency.
Table 7 also shows the beta coefficients for each stratum. Beta 1 corresponds to the
effect of the minor allele of the indicated SNP on plasma adiponectin concentrations in the
low adherence to the Mediterranean diet, and beta 2 indicates the regression coefficient
for the minor allele for high adherence to the Mediterranean diet. The MAF for the top-
ranked SNP (rs17249128) is high (0.466), being an interesting candidate SNP for further
investigation. Another very remarkable SNP in the top-ranked list of gene-diet interactions
is rs2917570 in OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like) on chro-
mosome 3. Interestingly, SNPs in the OPCML gene have been associated with adiponectin
concentrations in previous GWASs carried out in some European populations [35], but not
in others [35]. The existence of a gene-diet interaction may explain these previous results.
In our study, when adherence to the Mediterranean diet is low, the minor allele of the
rs2917570 SNP is associated with higher adiponectin concentrations (B = 0.113, p = 0.008).
However, when adherence to the Mediterranean diet is high, the minor allele is associated
with lower adiponectin concentrations (B= −0.118, p = 0.003); p for this SNP–Mediterranean
diet interaction is 5.1 × 10−6.
Figure 6 depicts such a gene-Mediterranean diet interaction in panels A (low adher-
ence) and B (high adherence). Additional adjustment for age, diabetes, BMI, smoking and
physical activity did not change the statistical significance level for the associations.
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Figure 6. Gene–diet interaction effect between the SNP rs2917570, located in the opioid-binding protein/cell adhesion 
molecule (OPCML), chromosome 11, and adherence to the Mediterranean diet: low adherence (panel (A)) and high adher-
ence (panel (B)) on plasma adiponectin concentrations (ln-transformed) in the whole population. p-values were obtained 
in the general linear regression models: unadjusted (1) and adjusted for sex, age, diabetes, BMI, smoking and physical 
activity (2). Error bars: (SE) of means. Genotype prevalence: AA (25%), AC (54%) and CC (21%). 
Finally, we would like to mention that we obtained a top-ranked gene-Mediterranean 
diet interaction signal (p = 1.5 × 10−5) involving PARP1 (Poly(ADP-Ribose) Polymerase 1). 
This gene has been related to adiponectin gene expression [69,70] and some dietary mod-
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Finally, we would like to mention that we obtained a top-ranked gene-Mediterranean
diet interaction signal (p = 1.5 × 10−5) involving PARP1 (Poly(ADP-Ribose) Polymerase 1).
This gene has been related to adiponectin gene expression [69,70] and some dietary modu-
lation has been reported in animal models [70,71].
4. Discussion
In this study carried out in a high-cardiovascular risk Mediterranean population,
we found that plasma adiponectin levels were higher in women and directly associated
with higher HDL-C and inversely associated with fasting triglycerides and fasting glucose
levels, as well as with lower type 2 diabetes risk, even after multivariate adjustment.
These findings are in accordance with many previous reports in other populations of
various ethnic backgrounds [72–76]. The robust linear inverse association between plasma
adiponectin concentrations and type 2 diabetes risk observed in our population, mainly in
women, is concordant with other reports where associations with adiponectin levels were
stronger in individuals with a higher metabolic risk profile [77–79], supporting the idea
that the association between adiponectin concentrations and type 2 diabetes is stronger in
subjects with higher BMI.
In our population, the direct and inverse associations between plasma adiponectin
and fasting glucose, type 2 diabetes or lipid levels remained statistically significant even
after adjustment for BMI. The mechanisms explaining these protective associations are far
from being determined, but there is some agreement suggesting that the anti-inflammatory
properties of adiponectin [15,80] are likely to be the major component of its beneficial
effects against insulin resistance [15–17,76,81,82]. However, in this study, we did not have
data on inflammation markers for most of the participants, so we were unable to analyze
these associations. We did, nevertheless, have data on genetic polymorphisms, both at the
candidate gene level and at the genome-wide level, and found some interesting suggestive
associations. Firstly, we set out to analyze the associations between four well-known
candidate SNPs in the ADIPOQ gene and plasma adiponectin levels, subsequently carrying
out an exploratory GWAS, given that very few reports have focused on Mediterranean
subjects (mainly those including Italian participants) and it is known that even though
specific GWAS-population associations may exist, they can misestimate across global
populations [83,84]. Although many GWASs have been carried out on adiponectin in
populations of Europe or with European ancestry in North America [35,41–45], the Spanish
Mediterranean population has not been included in these meta-analyses. Thus, it is
necessary to carry out specific studies on this population.
Despite the small sample size of our study (954 participants), we opted to undertake
an exploratory GWAS to at least identify the genetic variants most associated with plasma
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adiponectin levels in high-cardiovascular risk Mediterranean subjects. In previous studies
on Spanish Mediterranean individuals, we were able to detect, at the GWAS level of
significance, the main expected top-ranked SNPs in genes consistently associated with
several traits with a strong genetic influence (plasma bilirubin, polyunsaturated fatty acids
and bitter taste perception), with even smaller sample sizes [85–87]. For adiponectin, if
the genetic association between the main SNPs in candidate genes consistently reported
in other populations (ADIPOQ or CDH13) is strong, our sample size would be enough
to detect them at the GWAS level. Thus, in a previous GWAS carried out on a Korean
population [34], with an initial sample size similar to ours (about 950 participants), the
authors detected some statistically significant associations at the GWAS level with SNPs
in the CDH13 gene, which is more important in Asian populations than in European
ones [34–45]. In this Korean population [34], the top-ranked SNP was rs3865188-CDH13
with MAF: 0.309, reaching a p-value of 5 × 10−15. In our study, we did not detect any
association at the GWAS level (p < 5 × 10−8) or at the suggestive level of significance
(p < 1 × 10−5) with SNPs in the CDH13 gene and adiponectin concentrations.
In our exploratory GWAS, for adiponectin concentrations in the whole population,
we detected some signals at the suggestive level of GWAS significance (p < 1 × 10−5),
including the rs9738548 (intergenic) SNP on chromosome 12, the rs11647294-VAT1L SNP on
chromosome 16, the rs12149200-RAB40C SNP on chromosome 16 and the rs1124603-HPS5
SNP on chromosome 11, among others. As far as we know, this is the first time that our
top-ranked SNPs have been reported as being associated with adiponectin concentrations.
Some of these signals may be false positive associations, and replication, mainly in this
population and in other populations, is needed to confirm the signals. Several SNPs on
chromosome 12 have been identified as genome-wide signals in the adiponectin meta-
analysis of 45,891 individuals carried out by Dastani et al. [41]. These signals were the
following: rs601339-GPR109A; rs6488898-ATP6V0A2; rs7133378-DNAH10; rs7305864-
CCDC92; and rs7978610-ZNF664. Likewise, in this meta-analysis [41], several SNPs on
chromosome 16 reached the genome-wide level of significance. In addition to the strong
signals on CDH13, located on chromosome 16, other genome-wide signals included the
rs2925979-CMIP SNP. Our top-ranked SNPs also included two SNPs on chromosome 16
(rs11647294-VAT1L and rs12149200-RAB40C). Among these top-ranked SNPs for plasma
adiponectin in this high-cardiovascular risk Mediterranean population, we suggest that
an interesting candidate would be the rs11647294-VAT1L SNP. This SNP has a high MAF
(0.401), supporting a more stable association with adiponectin concentrations in comparison
with the potential bias related to low-frequency variants in studies with a small sample
size. Thus, it has been reported that common SNPs (MAF: 0.25–0.50) result in significantly
fewer false positives than for less common SNPs [88]. Moreover, we conducted a stratified
analysis per sex between the rs11647294-VAT1L SNP and adiponectin concentrations in
men and women, and we observed statistically significant associations in both men and
women strata, therefore increasing the level of evidence against a false positive association.
The VAT1L gene has been associated with schizophrenia in some GWASs and subsequent
pathway enrichment analysis suggested its involvement in neural and immune system-
related pathways [89]. Likewise, the VAT1L gene has been associated with the von Economo
neurons in brain functional analyses [90] and in calcific aortic valve disease [91], among
other diseases [92,93]. Functionally, the VAT1L gene has been linked to several immune
system pathways [89,91], and adiponectin levels could be related to these pathways [15,94].
Regarding the ADIPOQ SNPs, we did not identify such SNPs among the top-ranked
in any of the GWAS strata of this population, as initially expected according to the GWASs
carried out in several European populations [41–45]. We, therefore, proceeded to extract
all the ADIPOQ SNPs that were in the array to carry out a more detailed study. For the
ADIPOQ gene, the number of SNPs included in the array was low (n = 10) and none of
them showed statistical significance at the p < 0.05 level. The most significant, although
without reaching p < 0.05, was rs1501299, which had already been previously analyzed in
our initial list of the four pre-selected candidate SNPs in the ADIPOQ gene, therefore being
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consistent with our previous findings. The association between the candidate SNPs +276G
> T (rs1501299) and +45T > G (rs2241766) with plasma adiponectin has been heterogeneous
across diverse populations [29,41,46–50,95,96]. Of the four candidate SNPs analyzed,
we only observed strong and additive associations for the −11391 G/A (rs17300539)
polymorphism, in agreement with several studies showing significant associations for this
variant [49,50]. However, we did not find any significant association for the rs17366568
(G > A) SNP, which was the SNP most significantly associated with adiponectin levels in
the meta-analysis carried out by Heid et al. in European populations [35]. Interestingly, in
this meta-analysis, despite the global association, when we look at specific populations, in
agreement with our results, the rs17366568 SNP did not reach statistical significance for
the only Mediterranean population analyzed (Italian subjects from the InChianti study,
Italy) [35], therefore increasing the evidence of potential population-specific differences.
On the other hand, the −11391 G/A (rs17300539) polymorphism in the ADIPOQ
gene was significantly associated (p = 7.2 × 10−5) with adiponectin concentrations in our
Mediterranean population in the separate candidate gene analysis. However, we did not
observe such association in the GWAS because this SNP was not included in the array. If
we had carried out an imputation analysis, we could have possibly detected this signal or
that of other SNPs in the ADIPOQ gene among the top-ranked, but without reaching the
GWAS level (because this association, despite being high, did not reach the GWAS level
of statistical significance, nor the suggestive significance level, although being close). In
our case, we preferred to undertake the exploratory GWAS with directly analyzed SNPs
without using imputations in order to avoid the bias due to low imputation quality due to
a not very large sample size.
Furthermore, we carried out sex-specific and diabetes-specific GWASs to detect if the
high-cardiovascular risk characteristics of our population provide a profile of associations
in candidate genes that differs from the most commonly studied populations in other
GWASs, from which diabetic subjects are sometimes excluded and which generally include
a younger population with a lower cardiovascular risk. Having consulted the published
GWAS results in greater detail [34–45], we observed that although the greatest associations
are found for SNPs in the ADIPOQ and CDH13 genes, the other top-ranked genes differ
widely between populations, indicating great heterogeneity in the findings depending on
the participant characteristics. This fact deserves much more attention, since the SNPs
in the two top-ranked genes explain a very low percentage of adiponectin variance and
there will surely be many other genes associated with it, but whose contribution may
be highly variable and dynamic depending on the geographic origin, age, sex and the
presence or absence of obesity and/or diabetes in the analyzed populations. Therefore,
subsequent studies should take this perspective into account when interpreting the results
and undertaking statistical analyses by presenting more information on the top-ranked
SNPs in each population analyzed, instead of presenting the summary of GWAS meta-
analyses.
One limitation of our study is the small sample size compared with other GWASs
undertaken on other populations. This limits its statistical power, as clearly it would
have been much better to have studied a larger population. However, as the Spanish
Mediterranean population is under-represented in the studies published so far, it is of great
interest to have these results available, given that they are the first on this population.
Moreover, despite our small sample size, in our exploratory gene–diet interaction
study, we detected some suggestive gene-Mediterranean diet interactions on analyzing
SNPs at the genome-wide level. Among them, we consider as promising for further analysis
the interaction found with the rs2917570 SNP in the OPCML gene. SNPs in this gene have
been associated with adiponectin concentrations in previous GWASs in some European
populations [35], but replication is low. The existence of a gene–diet interaction may help to
explain some previous inconsistent results. Likewise, another relevant gene-Mediterranean
diet interaction to be explored in further studies is that involving the PARP1 gene. This
gene has been related to adiponectin gene expression in functional studies [69,70] and
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some dietary modulation has been reported in adipose tissue of mice in response to high-
fat diet feeding or calorie restriction [71]. These previous results contribute to increase
the importance of the observed gene-Mediterranean diet interaction encompassing the
rs3219110-PARP1 polymorphism. As this work is only statistical and exploratory, we
could not undertake a mechanistic study to suggest potential mechanisms explaining these
SNP–diet interactions. With our results, other authors will be able to carry out additional
studies to better characterize the possible interaction mechanisms.
5. Conclusions
Our results indicate that plasma adiponectin is strongly associated with a favorable
lipid profile (high HDL-C and low triglycerides) and inversely related to type 2 diabetes
risk in this high-cardiovascular risk Mediterranean population, in agreement with previous
results in diverse populations. However, the genetic variants more associated with plasma
adiponectin concentrations could be population-specific and influenced by sex and diabetes
status. Moreover, in our exploratory analysis, despite the small sample size, we detected
some suggestive gene-Mediterranean diet interactions at the GWAS level that may be
interesting for further characterization in later studies in this population and in other
populations.
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